Table 3 Clinical utility comparison of IHC TPS and RNA-seq rank results
From: Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Prediction Method | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
Melanoma IHC ≥1% | 31.3% | 81.8% | 55.6% | 62.1% |
Melanoma RNA-seq > 75 | 25.0% | 93.2% | 72.7% | 63.1% |
Melanoma IHC ≥1% & RNA-seq > 75 | 20.8% | 94.6% | 71.4% | 64.8% |
NSCLC IHC ≥1% | 58.8% | 60.6% | 26.3% | 71.4% |
NSCLC IHC ≥50% | 47.1% | 84.5% | 42.1% | 87.0% |
NSCLC RNA-seq > 75 | 58.8% | 64.8% | 28.6% | 86.8% |
NSCLC IHC ≥1% & RNA-seq > 75 | 63.6% | 68.0% | 30.4% | 89.5% |
NSCLC IHC ≥50% & RNA-seq > 75 | 46.2% | 83.9% | 37.5% | 88.1% |
RCC IHC ≥1% | 28.6% | 92.1% | 40.0% | 87.5% |
RCC RNA-seq > 75 | 42.9% | 84.2% | 33.3% | 88.9% |
RCC IHC ≥1% & RNA-seq > 75 | 33.3% | 93.9% | 50.0% | 88.6% |